ArriVent BioPharma, Inc. (AVBP) vs Verastem, Inc. (VSTM)
A side-by-side comparison of ArriVent BioPharma, Inc. and Verastem, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$14.80HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
VSTM
Verastem, Inc.
$7.81HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — AVBP vs VSTM
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)VSTM -25.7% (-9.4%/yr)AVBP compounded faster over this window
AVBP VSTM
AVBP vs VSTM: by the numbers
- •AVBP is the larger company ($689M vs $686M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -231.59% net margin).
Metrics side by side
Valuation
| Metric | AVBP | VSTM |
|---|---|---|
| P/S ratio | N/A | 7.84 |
| P/B ratio | 1.88 | 13.72 |
Profitability
| Metric | AVBP | VSTM |
|---|---|---|
| Gross margin | 0.00% | 86.69% |
| Operating margin | 0.00% | -550.33% |
| Net margin | 0.00% | -231.59% |
| ROE | -44.63% | -405.51% |
| ROIC | -47.96% | -118.97% |
Growth (annualized)
| Metric | AVBP | VSTM |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -18.98% |
| Total return CAGR (5Y) | N/A | -25.22% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.